Drug Development

Virostat evaluated in phase II trial for hepatitis C

Published in Hepatitis Weekly, March 14th, 2005

Bioenvision, Inc., (BIVN) announced that the first patients have been enrolled in a multicenter, international phase II clinical trial to evaluate the clinical efficacy of Virostat for the treatment of chronic hepatitis C.

The investigator-sponsored trial is being conducted at specialist centers in Europe and Egypt and will assess the ability of Virostat to reduce viral load and improve quality of life in patients with chronic hepatitis C.

"This begins a new phase of development for Bioenvision, and we look forward to the opportunity to build value in our non-cancer related franchises," said Chris Wood, chairman and CEO of Bioenvision. He added,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry